Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Travera Inc
Alliance for Clinical Trials in Oncology
Iovance Biotherapeutics, Inc.
Eastern Cooperative Oncology Group
AstraZeneca
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Mayo Clinic
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
University Health Network, Toronto
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
ViroMissile, Inc.
Children's Oncology Group
Dana-Farber Cancer Institute
Kaiser Permanente
Children's Oncology Group
Washington University School of Medicine
Essen Biotech
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
MacroGenics
Indiana University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
University of Nebraska
University of Florida
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Immatics US, Inc.
University of Southern California
Indiana University
Swiss Cancer Institute
Degron Therapeutics Co.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
University Health Network, Toronto
Memorial Sloan Kettering Cancer Center
Transgene